Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells.
BNIP3
HIF
hepatocarcinoma
hypoxia
resistance
sorafenib
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Dec 2019
09 Dec 2019
Historique:
received:
30
10
2019
revised:
27
11
2019
accepted:
06
12
2019
entrez:
15
12
2019
pubmed:
15
12
2019
medline:
15
12
2019
Statut:
epublish
Résumé
Despite sorafenib effectiveness against advanced hepatocarcinoma (HCC), long-term exposure to antiangiogenic drugs leads to hypoxic microenvironment, a key contributor to chemoresistance acquisition. We aimed to study the role of hypoxia in the development of sorafenib resistance in a human HCC in vitro model employing the HCC line HepG2 and two variants with acquired sorafenib resistance, HepG2S1 and HepG2S3, and CoCl
Identifiants
pubmed: 31835431
pii: cancers11121984
doi: 10.3390/cancers11121984
pmc: PMC6966438
pii:
doi:
Types de publication
Journal Article
Langues
eng
Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Mol Oncol. 2019 Feb;13(2):403-421
pubmed: 30536571
J Cell Physiol. 2012 Apr;227(4):1319-25
pubmed: 21604268
Breast Cancer Res. 2014 Jul 28;16(4):R78
pubmed: 25069832
Oncol Lett. 2015 Aug;10(2):778-784
pubmed: 26622569
Biochem Biophys Res Commun. 2012 Feb 17;418(3):531-6
pubmed: 22285185
J Gastroenterol. 2005 May;40(5):504-10
pubmed: 15942716
Exp Mol Med. 2018 Oct 12;50(10):134
pubmed: 30315182
Ann Surg Oncol. 2007 May;14(5):1752-62
pubmed: 17195906
J Cancer. 2017 Apr 9;8(7):1187-1196
pubmed: 28607593
Cancers (Basel). 2019 May 30;11(6):null
pubmed: 31151160
Cell Biosci. 2017 Dec 16;7:71
pubmed: 29270287
PLoS One. 2014 Dec 22;9(12):e115565
pubmed: 25531114
Cancer Res. 2011 Nov 1;71(21):6807-16
pubmed: 21911457
Cancer Lett. 2013 Feb 1;329(1):74-83
pubmed: 23111106
Br J Cancer. 2017 Nov 7;117(10):1518-1528
pubmed: 28926527
Anticancer Drugs. 2007 Jul;18(6):633-9
pubmed: 17762391
Sci Rep. 2016 Aug 01;6:30483
pubmed: 27476430
Cancer Res. 2006 Dec 15;66(24):11851-8
pubmed: 17178882
Iran J Pharm Res. 2018 Winter;17(1):1-10
pubmed: 29755534
J Pineal Res. 2010 Sep;49(2):193-200
pubmed: 20609075
Oncogene. 2007 Jan 4;26(1):132-41
pubmed: 16799636
Int J Oncol. 2004 May;24(5):1279-88
pubmed: 15067352
Technol Cancer Res Treat. 2014 Feb;13(1):77-86
pubmed: 23862748
J Hepatol. 2016 Aug;65(2):314-24
pubmed: 27154061
Acta Pharmacol Sin. 2017 Dec;38(12):1642-1654
pubmed: 28713155
Oncotarget. 2017 Jun 28;8(38):63208-63222
pubmed: 28968982
J Vet Diagn Invest. 2003 Nov;15(6):585-8
pubmed: 14667025
J Cell Physiol. 2018 Jan;234(1):692-708
pubmed: 30132846
Mol Cell Proteomics. 2015 Jun;14(6):1527-45
pubmed: 25850433
Prostate. 2016 Feb;76(2):199-206
pubmed: 26447830
Chemotherapy. 2012;58(6):445-53
pubmed: 23364257
Med Oncol. 2015 Jan;32(1):419
pubmed: 25487445
Medicina (Kaunas). 2019 Aug 23;55(9):null
pubmed: 31450841
J Pineal Res. 2016 Oct;61(3):396-407
pubmed: 27484637
J Hepatol. 2011 Aug;55(2):359-68
pubmed: 21168458
Hepatology. 2013 May;57(5):1847-57
pubmed: 23299930
Mol Pharmacol. 2017 Sep;92(3):246-255
pubmed: 28242743
J Hepatol. 2011 Feb;54(2):328-39
pubmed: 21056497
Cancer Lett. 2014 Dec 1;355(1):96-105
pubmed: 25218350
Biochem Biophys Res Commun. 2019 Jun 4;513(3):642-650
pubmed: 30981500
Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):564-570
pubmed: 29054475
Oncogene. 2005 Jun 23;24(27):4421-32
pubmed: 15856026
Oncol Rep. 2019 Mar;41(3):1759-1768
pubmed: 30569180
J Hepatol. 2010 May;52(5):698-704
pubmed: 20347499
J Clin Invest. 2018 Jan 2;128(1):369-380
pubmed: 29227282
Cell Death Discov. 2019 Jul 19;5:120
pubmed: 31341646
Mol Cancer Ther. 2014 Jun;13(6):1589-98
pubmed: 24705351
Leuk Res. 2010 Mar;34(3):364-72
pubmed: 19732952
World J Clin Oncol. 2017 Jun 10;8(3):203-213
pubmed: 28638790
Oncotarget. 2017 Aug 24;8(53):91402-91414
pubmed: 29207653
PLoS One. 2012;7(11):e50407
pubmed: 23209735
Mol Cells. 2011 Jun;31(6):579-83
pubmed: 21573703
Sci Rep. 2018 Jun 26;8(1):9706
pubmed: 29946188
J Gene Med. 2017 Dec;19(12):null
pubmed: 29106062
J Cell Sci. 2012 Jan 1;125(Pt 1):133-43
pubmed: 22250201
Clin Cancer Res. 2005 Feb 1;11(3):1021-7
pubmed: 15709167
Pharmacol Ther. 2016 Aug;164:152-69
pubmed: 27139518
Acta Pharmacol Sin. 2017 May;38(5):614-622
pubmed: 28344323
Hepatology. 2010 Oct;52(4):1310-21
pubmed: 20799354
J Hematol Oncol. 2016 Mar 08;9:20
pubmed: 26957312
Cell Signal. 2014 May;26(5):1030-9
pubmed: 24486412
Mol Biol Rep. 2014 Nov;41(11):7705-14
pubmed: 25096512
Cancer Lett. 2015 Oct 10;367(1):1-11
pubmed: 26170167
J Mol Med (Berl). 2016 Jun;94(6):613-27
pubmed: 27094811
Int J Oncol. 2019 Jan;54(1):348-360
pubmed: 30365137
Clin Cancer Res. 2012 Oct 15;18(20):5662-71
pubmed: 22929805